Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | neuropeptide receptor A26 | 0.0501 | 1 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.005 | 0.0167 | 0.5 |
Onchocerca volvulus | 0.0042 | 0 | 0.5 | |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.005 | 0.0167 | 0.5 |
Echinococcus multilocularis | neuropeptide s receptor | 0.0501 | 1 | 1 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.005 | 0.0167 | 0.5 |
Echinococcus multilocularis | neuropeptide receptor A26 | 0.0501 | 1 | 1 |
Loa Loa (eye worm) | leucine Rich Repeat family protein | 0.0165 | 0.2685 | 1 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.005 | 0.0167 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.